Protara Therapeutics, Inc. (TARA)

NGM – Real Time Price. Currency in USD

3.89

-0.02 (-0.51%)

Market open: Aug 12, 2026, 10:17 AM EDT

3.96

+0.05 (1.28%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

11.08.2026

Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline

Protara Therapeutics is rated Buy, with a risk-adjusted fair value of $9.96 per share versus the current ~$4 price. TARA-002 targets NMIBC and Lymphatic Malformations; orphan drug indications offer significant upside, despite NMIBC's competitive landscape and lower CR rates. IV Choline Chloride, targeting severe choline deficiency in parenteral nutrition patients, could generate substantial revenue if approved, with pivotal data expected in 2026.

Videos

No Data

There is no data to display

Protara Therapeutics, Inc. (TARA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Protara Therapeutics, Inc. (TARA)

Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline

Videos

No Data

Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline

Videos

No Data

Search stocks

Protara Therapeutics, Inc. (TARA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Protara Therapeutics, Inc. (TARA)

Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline

Videos

No Data

Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline

Videos

No Data